Alkermes (NASDAQ:ALKS) Releases Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Alkermes (NASDAQ:ALKS) released its earnings results on Wednesday. The company reported $0.92 earnings per share for the quarter, beating analysts’ consensus estimates of $0.81 by $0.11, Zacks reports. Alkermes had a return on equity of 24.92% and a net margin of 22.15%. Alkermes updated its FY 2025 guidance to 1.030-1.210 EPS.

Alkermes Stock Up 3.0 %

Alkermes stock traded up $0.96 during midday trading on Wednesday, reaching $32.92. The company’s stock had a trading volume of 680,089 shares, compared to its average volume of 1,506,600. The stock has a market capitalization of $5.33 billion, a P/E ratio of 16.88, a PEG ratio of 1.83 and a beta of 0.49. Alkermes has a 52-week low of $22.90 and a 52-week high of $33.00. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.45 and a quick ratio of 3.03. The stock’s 50-day simple moving average is $30.16 and its 200-day simple moving average is $28.65.

Insider Transactions at Alkermes

In other Alkermes news, EVP Craig C. Hopkinson sold 100,918 shares of the company’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $32.05, for a total value of $3,234,421.90. Following the sale, the executive vice president now directly owns 44,290 shares of the company’s stock, valued at approximately $1,419,494.50. This represents a 69.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Christian Todd Nichols sold 5,208 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total value of $151,813.20. Following the sale, the senior vice president now directly owns 60,703 shares in the company, valued at approximately $1,769,492.45. This trade represents a 7.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 179,189 shares of company stock worth $5,723,518. Company insiders own 4.89% of the company’s stock.

Wall Street Analysts Forecast Growth

ALKS has been the subject of a number of analyst reports. HC Wainwright reissued a “neutral” rating and set a $37.00 price objective on shares of Alkermes in a research note on Friday, October 25th. Mizuho increased their price target on shares of Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Deutsche Bank Aktiengesellschaft began coverage on shares of Alkermes in a research report on Tuesday. They issued a “buy” rating and a $40.00 price objective on the stock. JPMorgan Chase & Co. dropped their target price on shares of Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Finally, The Goldman Sachs Group reduced their price target on Alkermes from $32.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, October 25th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $36.33.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.